Spots Global Cancer Trial Database for recurrent childhood medulloblastoma

Every month we try and update this database with for recurrent childhood medulloblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment	NCT00822458	Recurrent Child...	vismodegib laboratory biom... pharmacological...	3 Years - 21 Years	National Cancer Institute (NCI)
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	NCT00053963	Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi...	romidepsin	- 21 Years	National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma	NCT00006102	Brain and Centr... Lymphoma Neuroblastoma Retinoblastoma Sarcoma Unspecified Chi...	becatecarin	- 21 Years	National Cancer Institute (NCI)
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors	NCT00002647	Brain and Centr... Metastatic Canc...	verteporfin conventional su...	3 Years - 70 Years	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer	NCT00025558	Brain and Centr...	filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo...	1 Year - 49 Years	NYU Langone Health
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	NCT00002608	Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma	cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera...	- 65 Years	National Cancer Institute (NCI)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors	NCT00003765	Brain and Centr...	O6-benzylguanin... carmustine	- 21 Years	National Cancer Institute (NCI)
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer	NCT00025558	Brain and Centr...	filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo...	1 Year - 49 Years	NYU Langone Health
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors	NCT00025077	Brain and Centr...	filgrastim carboplatin cyclophosphamid... thiotepa conventional su... peripheral bloo... radiation thera...	- 20 Years	National Cancer Institute (NCI)
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment	NCT00822458	Recurrent Child...	vismodegib laboratory biom... pharmacological...	3 Years - 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors	NCT00002594	Brain Tumor Central Nervous...	Sargramostim cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo...	2 Years - 25 Years	Children's Oncology Group
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors	NCT00098761	Brain and Centr...	laromustine	- 21 Years	Pediatric Brain Tumor Consortium
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma	NCT00070525	Childhood High-... Childhood Oligo... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	tipifarnib	- 21 Years	National Cancer Institute (NCI)
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors	NCT02271711	Recurrent Child... Recurrent Epend... Recurrent Medul...	Laboratory Biom... Natural Killer ...	- 21 Years	M.D. Anderson Cancer Center
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	NCT00381797	Childhood Cereb... Childhood Oligo... Childhood Spina... Recurrent Child... Recurrent Child... Recurrent Child...	Bevacizumab Fludeoxyglucose... Irinotecan Hydr...	- 21 Years	National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors	NCT00095940	Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona...	- 21 Years	National Cancer Institute (NCI)
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma	NCT00360854	Brain and Centr...	erlotinib hydro... mutation analys... polymorphism an... laboratory biom... pharmacological... radiation thera...	1 Year - 21 Years	National Cancer Institute (NCI)
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	NCT02255461	Childhood Choro... Childhood Epend... Childhood Grade... Childhood High-... Childhood High-... Childhood Medul... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	palbociclib ise... pharmacological... laboratory biom...	4 Years - 21 Years	Pediatric Brain Tumor Consortium
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors	NCT00098761	Brain and Centr...	laromustine	- 21 Years	Pediatric Brain Tumor Consortium
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma	NCT00363272	Childhood Burki... Childhood Centr... Childhood Choro... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Unspecified Chi...	ispinesib laboratory biom... pharmacological...	1 Year - 21 Years	National Cancer Institute (NCI)
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors	NCT01158300	Brain and Centr...	VEGF inhibitor ...	3 Years - 21 Years	Pediatric Brain Tumor Consortium
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	NCT01132547	Cancer	cyproheptadine ... placebo	2 Years - 21 Years	University of South Florida
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors	NCT00095940	Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	lapatinib ditos... therapeutic con... laboratory biom... pharmacological... positron emissi... magnetic resona...	- 21 Years	National Cancer Institute (NCI)
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors	NCT00006247	Brain and Centr...	semaxanib	- 21 Years	Pediatric Brain Tumor Consortium
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer	NCT00014573	Brain and Centr...	aldesleukin autologous tumo... filgrastim sargramostim therapeutic aut... carmustine cisplatin cyclophosphamid... paclitaxel autologous bone... conventional su... peripheral bloo...	- 65 Years	Barbara Ann Karmanos Cancer Institute
Cilengitide in Treating Children With Refractory Primary Brain Tumors	NCT00063973	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	cilengitide laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers	NCT00002752	Brain and Centr... Metastatic Canc...	iodine I 131 mo...	3 Years -	Duke University
Lobradimil and Carboplatin in Treating Children With Brain Tumors	NCT00019422	Brain and Centr...	carboplatin lobradimil	- 21 Years	National Cancer Institute (NCI)
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	NCT02194452	Acoustic Schwan... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Choroid P... Adult Craniopha... Adult Diffuse A... Adult Ependymob... Adult Ependymom... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Grade I M... Adult Grade II ... Adult Medullobl... Adult Meningeal... Adult Mixed Gli... Adult Myxopapil... Adult Oligodend... Adult Papillary... Adult Pilocytic... Adult Pineal Gl... Adult Pineoblas... Adult Pineocyto... Adult Subependy... Adult Subependy... Adult Supratent... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Supra... Meningeal Melan... Newly Diagnosed... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child...	gallium Ga 68-e... positron emissi... computed tomogr... laboratory biom...	6 Months - 29 Years	University of Iowa
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	NCT00053963	Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi...	romidepsin	- 21 Years	National Cancer Institute (NCI)
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors	NCT00002594	Brain Tumor Central Nervous...	Sargramostim cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo...	2 Years - 25 Years	Children's Oncology Group
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors	NCT00238173	Bone Marrow Sup... Brain and Centr... Drug/Agent Toxi... Long-term Effec...	filgrastim acetylcysteine carboplatin cyclophosphamid... etoposide phosp... mannitol sodium thiosulf...	1 Year - 18 Years	OHSU Knight Cancer Institute
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	NCT02255461	Childhood Choro... Childhood Epend... Childhood Grade... Childhood High-... Childhood High-... Childhood Medul... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	palbociclib ise... pharmacological... laboratory biom...	4 Years - 21 Years	Pediatric Brain Tumor Consortium

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: